Showing 2691-2700 of 18644 results for "".
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
https://reachmd.com/programs/project-oncology/establishing-d-vrd-efficacy-for-transplant-ineligible-multiple-myeloma/30049/Read about the effectiveness of adding daratumumab to the standard VRd regimen for patients with newly diagnosed multiple myeloma.A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/Join Drs. Armstrong and Stein Gold as they evaluate the clinical evidence and potential role of emerging oral systemic therapies in moderate to severe psoriasis.The Impact of Zero in Rheumatology
https://reachmd.com/programs/medical-industry-feature/the-impact-of-zero-in-rheumatology/32264/Most patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis have symptoms across multiple domains.1-2 In fact, when patients meet certain outcome measures, like ACR50 or ASAS40, they may still have active disease that disrupts everyday life.3-5 And paIntegrating Palliative Care in Pulmonary Hypertension
https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.Treating Primary Biliary Cholangitis with Seladelpar: Insights from the RESPONSE Trial
https://reachmd.com/programs/gi-insights/treating-primary-biliary-cholangitis-with-seladelpar-insights-from-the-response-trial/29162/Based on the RESPONSE trial, seladelpar may be a safe and effective treatment for primary biliary cholangitis patients who don’t response to current therapies.Healthy lifestyle interventions for CVD risk reduction in secondary prevention
https://reachmd.com/cme/obesity/healthy-lifestyle-interventions-for-cvd-risk-reduction-in-secondary-prevention/17755/3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MDICI Combination Regimens for First-Line Treatment of Metastatic ESCC
https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/Explore emerging data, guideline recommendations, and AE management for first-line anti-PD-1 and chemotherapy regimens in metastatic ESCC.Improving Symptoms in Patients with HFrEF Using Novel Device Therapy
https://reachmd.com/programs/cme/improving-symptoms-in-patients-with-hfref-using-novel-device-therapy/14475/Baroreflex activation therapy (BAT) provides durable and sustained benefits for exercise capacity, functional status, and QoL. Tune in to learn more!Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
https://reachmd.com/programs/cme/chairperson-perspective-improving-hrher2-breast-cancer-outcomes-with-trop2-antibody-drug-conjugates/29875/Learn about TROP2-directed antibody-drug conjugates and their role in the treatment of HR+, HER2- metastatic breast cancer.Impacts of Patients Underreporting COPD Exacerbations
https://reachmd.com/programs/deep-breaths-updates-chest/impacts-of-patients-underreporting-copd-exacerbations/11494/There are treatment options available for COPD, but how can we manage those patients who underreport their symptoms and exacerbation history?